Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07441408 · ClinicalTrials.gov registry record · Phase 3
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Not yet
- Registry status
- Phase 3
- Development phase
- 2,277
- Enrollment target
NCT07441408: Clinical Trial Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT07441408 is a Phase 3 study that has not yet begun recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 2,277 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (195% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07441408, a Phase 3 study, has not yet begun recruiting, sponsored by Bristol-Myers Squibb.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,277 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).
Interventions
- DRUG BMS-986278
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,277 participants |
| Start Date | 2026-12-16 |
| Est. Completion | 2030-03-30 |
| Phase | Phase 3 |
What is known before NCT07441408 opens enrollment
NCT07441408 is an interventional study that assigns participants to a tested intervention. Its 2,277 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (195% higher).
The record links to 0 conditions, and to 1 intervention - of which BMS-986278 is the first listed.
NCT07441408 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07441408 about?
NCT07441408 is a clinical study titled "Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis". The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).
What is the current status of trial NCT07441408?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 2,277 participants. The study started on 2026-12-16. Estimated completion is 2030-03-30.
What interventions are being tested in trial NCT07441408?
The interventions under investigation include: BMS-986278 (DRUG).
Who is sponsoring clinical trial NCT07441408?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07441408's enrollment target sits among peer trials
2,277 94th of 2000 higher than 1,907 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03968393 · 2,270 participants · Phase 4
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
- NCT05530343 · 2,298 participants · NA
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
- NCT04124120 · 2,300 participants · NA
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
- NCT05237258 · 2,300 participants · NA
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI